| ALX Oncology to Host R&D Webcast Event Highlighting its Novel EGFR Targeting Antibody-Drug Conjugate, ALX2004, on May 20, 2025 |
SOUTH SAN FRANCISCO, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or the "Company") (Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients' lives, today announced that it will host a webcast event on May 20, 2025, to provide an update on ALX2004, the Company's potentially best- and first-in-class investigational antibody-drug conjugate (ADC). The webcast will highlight the novel mechanism of action, preclinical data and clinical development strategy for ALX2004 following clearance of the Investigational New Drug application from the U.S. Food and Drug Administration earlier this year. |
globenewswire.com |
2025-05-13 12:00:00 |
Czytaj oryginał (ang.) |
| All You Need to Know About Alexander's (ALX) Rating Upgrade to Strong Buy |
Alexander's (ALX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. |
zacks.com |
2025-05-08 17:05:34 |
Czytaj oryginał (ang.) |
| ALX Oncology Reports First Quarter 2025 Financial Results and Provides Corporate Update |
Following announcement of prioritized development strategy for evorpacept in combination with anti-cancer antibodies at R&D Day in March, Company is on track to initiate Phase 2 ASPEN-Breast and Phase 1 ASPEN-CRC studies in mid-2025 IND clearance received from U.S. FDA for novel EGFR-targeted antibody-drug conjugate (ADC), ALX2004, paving way for mid-year clinical program initiation; Company to host webcast focused on ALX2004 research program on May 20 Company will not pursue U.S. registrational path in gastric cancer following receipt of FDA feedback that accelerated approval pathway is not feasible based on ASPEN-06 due to standard-of-care evolving to ENHERTU® Data milestones expected across Company's three clinical programs in 2026 Cash runway has been extended into Q4 2026 SOUTH SAN FRANCISCO, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients' lives, today reported financial results for the first quarter ended March 31, 2025, and provided a corporate update. |
globenewswire.com |
2025-05-08 12:30:00 |
Czytaj oryginał (ang.) |
| Alexander's (ALX) Q1 FFO Beat Estimates |
Alexander's (ALX) came out with quarterly funds from operations (FFO) of $4.06 per share, beating the Zacks Consensus Estimate of $3.57 per share. This compares to FFO of $4.98 per share a year ago. |
zacks.com |
2025-05-05 15:05:33 |
Czytaj oryginał (ang.) |
| Alexander's Announces First Quarter Financial Results |
PARAMUS, N.J., May 05, 2025 (GLOBE NEWSWIRE) -- ALEXANDER'S, INC. (New York Stock Exchange: ALX) filed its Form 10-Q for the quarter ended March 31, 2025 today and reported: |
globenewswire.com |
2025-05-05 12:58:00 |
Czytaj oryginał (ang.) |
| ALX Oncology to Report First Quarter 2025 Financial Results on May 8, 2025 |
SOUTH SAN FRANCISCO, Calif., May 02, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or the “Company”) (Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients' lives, today announced plans to report its first quarter 2025 financial results on Thursday, May 8th, 2025, before market open. |
globenewswire.com |
2025-05-02 12:00:00 |
Czytaj oryginał (ang.) |
| Sell These 10 REITs While You Still Can |
This neither the best of times nor the worst of times for REIT investors. This article presents a list of 10 REITs that would merit a Sell rating even in the best of times, given their current condition. All 10 REITs face significant risks due to revenue shrinkage, and most are struggling with heavy indebtedness and a high risk of dividend cuts. |
seekingalpha.com |
2025-05-01 10:34:00 |
Czytaj oryginał (ang.) |
| Alexander's Declares Quarterly $4.50 Dividend on Common Shares |
PARAMUS, N.J., April 30, 2025 (GLOBE NEWSWIRE) -- Alexander's, Inc. (NYSE: ALX) today announced that its Board of Directors has declared a regular quarterly dividend of $4.50 per share payable on May 30, 2025 to stockholders of record on May 12, 2025. |
globenewswire.com |
2025-04-30 15:39:00 |
Czytaj oryginał (ang.) |
| ALX Oncology Announces Encouraging Final Results from Phase 1 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with B-cell Non-Hodgkin Lymphoma |
- Data to be presented at AACR 2025 Annual Meeting suggest the combination of ALX Oncology's investigational CD47-blocker, evorpacept, plus rituximab and lenalidomide (R 2 ) was well-tolerated and demonstrated promising anti-tumor activity |
globenewswire.com |
2025-04-25 17:10:00 |
Czytaj oryginał (ang.) |
| ALX Oncology Reports ASPEN-03 and ASPEN-04 Phase 2 Trials Evaluating Evorpacept with a Checkpoint Inhibitor for the Treatment of Head and Neck Cancers Did Not Meet Primary Endpoints |
SOUTH SAN FRANCISCO, April 25, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or the “Company”) (Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients' lives, today announced topline data from its Phase 2 ASPEN-03 and ASPEN-04 clinical trials. The company's investigational CD47-blocker evorpacept, when added to Merck's (known as MSD outside of the US and Canada) anti-PD-1 therapy, KEYTRUDA® (pembrolizumab) with or without chemotherapy, did not meet the primary endpoints in the ASPEN-03 and ASPEN-04 trials of improved objective response rates (ORR) as compared to historical controls of pembrolizumab alone and pembrolizumab with chemotherapy, respectively, as a first-line treatment in patients with advanced head and neck squamous cell carcinoma (HNSCC). The combination of evorpacept and pembrolizumab with or without chemotherapy in ASPEN-03 and ASPEN-04 demonstrated a manageable safety profile and was consistent with what has been previously reported for pembrolizumab and chemotherapy in this setting. Although the company will no longer pursue evorpacept in combination with pembrolizumab in HNSCC, multiple clinical trials of evorpacept in combination with anti-cancer antibodies will continue based on established proof-of-concept. |
globenewswire.com |
2025-04-25 13:00:00 |
Czytaj oryginał (ang.) |
| Alexander's Announces First Quarter Earnings Release Date and Vornado Realty Trust Quarterly Conference Call |
PARAMUS, N.J., April 24, 2025 (GLOBE NEWSWIRE) -- Alexander's, Inc. (NYSE: ALX) today announced that it will file its quarterly report on Form 10Q for the quarter ended March 31, 2025 with the U.S. Securities and Exchange Commission and issue its first quarter earnings release on Monday, May 5, 2025, before the New York Stock Exchange opens. |
globenewswire.com |
2025-04-24 16:13:00 |
Czytaj oryginał (ang.) |
| New Strong Buy Stocks for April 10th |
ALX, TAP, TEF, SFM and CBNA have been added to the Zacks Rank #1 (Strong Buy) List on April 10, 2025. |
zacks.com |
2025-04-10 12:20:41 |
Czytaj oryginał (ang.) |
| Best Income Stocks to Buy for April 10th |
ALX, TAP and TEF made it to the Zacks Rank #1 (Strong Buy) income stocks list on April 10, 2025. |
zacks.com |
2025-04-10 09:30:32 |
Czytaj oryginał (ang.) |
| Mousetraps: 9 High-Yield REITS With Potentially Unsafe Dividends |
The recent sell-off has increased the temptation to reach for some of the many high-yield REITs, but beware of "mousetrap" REITs with unsustainable dividends. Dividend safety is crucial; a cut can lead to plummeting share prices and reduced income, leaving investors with significant losses. Seeking Alpha Premium's Dividend Safety score helps identify risky REITs; grades range from A+ (safe) to F (high risk of cuts). |
seekingalpha.com |
2025-04-07 11:30:00 |
Czytaj oryginał (ang.) |
| New Strong Buy Stocks for April 3rd |
NATL, BGC, NPSNY, ALX and VEEV have been added to the Zacks Rank #1 (Strong Buy) List on April 3, 2025. |
zacks.com |
2025-04-03 11:40:35 |
Czytaj oryginał (ang.) |
| Best Income Stocks to Buy for April 3rd |
ALX, AVGO and BNPQY made it to the Zacks Rank #1 (Strong Buy) income stocks list on April 3, 2025. |
zacks.com |
2025-04-03 07:55:29 |
Czytaj oryginał (ang.) |
| Is Alexander's (ALX) Stock Outpacing Its Finance Peers This Year? |
Here is how Alexander's (ALX) and Banco Bilbao (BBVA) have performed compared to their sector so far this year. |
zacks.com |
2025-04-02 14:40:40 |
Czytaj oryginał (ang.) |
| Alexander's (ALX) Upgraded to Strong Buy: Here's Why |
Alexander's (ALX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy). |
zacks.com |
2025-03-28 15:00:27 |
Czytaj oryginał (ang.) |
| Best Income Stocks to Buy for March 28th |
ALX, HAFC and FFBC made it to the Zacks Rank #1 (Strong Buy) income stocks list on March 28, 2025. |
zacks.com |
2025-03-28 06:10:24 |
Czytaj oryginał (ang.) |
| 3 Dividend Stocks to Consider for a Market Rebound |
Magnifying the trend of positive earnings estimate revisions for these highly ranked stocks is their attractive dividends, which are reassuring as investors hope the broader market will continue to stabilize and rebound. |
zacks.com |
2025-03-25 20:45:18 |
Czytaj oryginał (ang.) |
| ALX Oncology to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025 |
SOUTH SAN FRANCISCO, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or the “Company”) (Nasdaq: ALXO), a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer and extend patients' lives, today announced plans to report its fourth quarter and full year 2024 financial results on Thursday, March 6th, 2025, before market open. |
globenewswire.com |
2025-02-27 10:00:00 |
Czytaj oryginał (ang.) |
| ALX Oncology to Host Virtual R&D Day on March 5, 2025 |
SOUTH SAN FRANCISCO, Calif., Feb. 18, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or the “Company”) (Nasdaq: ALXO), a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer and extend patients' lives, today announced that it will host a virtual Research and Development (R&D) Day webcast on Wednesday, March 5, 2025, at 6:00 a.m. |
globenewswire.com |
2025-02-18 10:00:00 |
Czytaj oryginał (ang.) |
| Inflation Isn't Dead Yet |
US equity markets flirted with fresh record-highs this week while benchmark interest rates hovered around two-month lows as investors weighed positive earnings news against uncomfortable hot inflation data. Complicating the policy outlook for the Federal Reserve, CPI data showed the fastest monthly rise in consumer prices since August, prompting a pledge from Powell for "more work to do." Snapping a two-week losing streak, the S&P 500 rebounded by 1.5%, closing fractionally below its prior record-high set in late January. The tech-heavy Nasdaq 100 rallied nearly 3%. |
seekingalpha.com |
2025-02-16 11:00:00 |
Czytaj oryginał (ang.) |
| Alexander's (ALX) Q4 FFO and Revenues Surpass Estimates |
Alexander's (ALX) came out with quarterly funds from operations (FFO) of $4.06 per share, beating the Zacks Consensus Estimate of $3.71 per share. This compares to FFO of $4.99 per share a year ago. |
zacks.com |
2025-02-10 13:25:20 |
Czytaj oryginał (ang.) |
| Alexander's Announces Fourth Quarter Financial Results |
PARAMUS, N.J., Feb. 10, 2025 (GLOBE NEWSWIRE) -- ALEXANDER'S, INC. (New York Stock Exchange: ALX) filed its Form 10-K for the year ended December 31, 2024 today and reported: |
globenewswire.com |
2025-02-10 11:15:00 |
Czytaj oryginał (ang.) |
| Alexander's Declares Quarterly $4.50 Dividend on Common Shares |
PARAMUS, N.J., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Alexander's, Inc. (NYSE: ALX) today announced that its Board of Directors has declared a regular quarterly dividend of $4.50 per share payable on February 28, 2025 to stockholders of record on February 18, 2025. |
globenewswire.com |
2025-02-05 15:00:00 |
Czytaj oryginał (ang.) |
| Alexander's: Bloomberg Lease Secured, Is The Dividend Safe |
Alexander's has dipped materially from its 52-week high following a spike in the US 10-year Treasury yield. The REIT generated fiscal 2024 third-quarter FFO of $2.84 per share, down from its year-ago comp. A $354.8 million cash and cash equivalents position helps to provide a buffer for the REIT, but 2025 debt maturities are heavy and will pose a challenge. |
seekingalpha.com |
2025-01-26 00:09:16 |
Czytaj oryginał (ang.) |
| ALX Oncology Presents Positive Updated Data from ASPEN-06 Phase 2 Trial Demonstrating Evorpacept Generates Strong Response and Durable Clinical Benefit in Patients with HER2-Positive Gastric Cancer |
SOUTH SAN FRANCISCO, Calif., Jan. 23, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or the “Company”) (Nasdaq: ALXO), a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer and extend patients' lives, announced positive updated data from the ASPEN-06 Phase 2 clinical trial demonstrating that the company's investigational CD47-blocker evorpacept generates a durable clinical response with a well-tolerated safety profile among patients with previously treated HER2-positive advanced gastric cancer (GC) or gastroesophageal junction (GEJ) cancer. The updated results, which build upon previously announced topline results, will be shared today in an oral presentation (Abstract #332) at the 2025 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium in San Francisco. |
globenewswire.com |
2025-01-23 10:00:00 |
Czytaj oryginał (ang.) |
| ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules |
SOUTH SAN FRANCISCO, Calif., Jan. 22, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings, Inc. (“ALX Oncology” or the “Company”), (Nasdaq: ALXO), a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer and extend patients' lives, today announced that effective January 21, 2025, the Compensation Committee of the Board of Directors of ALX Oncology granted an inducement stock option to purchase a total of 600,000 shares of ALX Oncology's common stock to Harish Shantharam, the Company's Chief Financial Officer, in connection with the commencement of his employment. Mr. Shantharam's inducement stock option is subject to the terms of the ALX Oncology Holdings Inc. 2025 Inducement Equity Incentive Plan and related forms of agreements, and were granted as inducements material to Mr. Shantharam to enter into employment with ALX Oncology in accordance with Nasdaq Listing Rule 5635(c)(4). |
globenewswire.com |
2025-01-22 18:01:00 |
Czytaj oryginał (ang.) |
| Alexander's Announces Fourth Quarter Earnings Release Date and Vornado Realty Trust Quarterly Conference Call |
PARAMUS, N.J., Jan. 22, 2025 (GLOBE NEWSWIRE) -- Alexander's, Inc. (NYSE: ALX) today announced that it will file its annual report on Form 10-K for the year ended December 31, 2024 with the U.S. Securities and Exchange Commission and issue its fourth quarter and full year earnings release on Monday, February 10, 2025, before the New York Stock Exchange opens. |
globenewswire.com |
2025-01-22 14:49:00 |
Czytaj oryginał (ang.) |
| ALX Oncology to Host Virtual Company Event Highlighting Updated Data from ASPEN-06 Phase 2 Trial Presented at 2025 ASCO GI |
SOUTH SAN FRANCISCO, Calif., Jan. 21, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or the “Company”) (Nasdaq: ALXO), a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer and extend patients' lives, today announced that the company will host a virtual event on Thursday, January 23, at 1:00 p.m. PT/4:00 p.m. ET to discuss updated data from the ASPEN-06 Phase 2 clinical trial evaluating the company's investigational CD47-blocker evorpacept in patients with previously treated HER2-positive advanced gastric cancer (GC) or gastroesophageal junction (GEJ) cancer. |
globenewswire.com |
2025-01-21 19:00:00 |
Czytaj oryginał (ang.) |
| ALX Oncology to Present Updated Results from Phase 2 ASPEN-06 Clinical Trial of Evorpacept in Patients with HER2-Positive Gastric Cancer in Oral Presentation at 2025 ASCO Gastrointestinal Cancers Symposium |
SOUTH SAN FRANCISCO, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer and extend patients' lives, today announced that the updated results from its Phase 2 ASPEN-06 clinical trial have been accepted for oral presentation at the 2025 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium, which will be held in San Francisco from January 23 - 25, 2025. |
globenewswire.com |
2024-12-18 10:00:00 |
Czytaj oryginał (ang.) |
| ALX Resources Corp. Receives Shareholder Approval for the Previously Announced Plan of Arrangement with Greenridge Exploration Inc. |
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES Vancouver, British Columbia--(Newsfile Corp. - December 2, 2024) - ALX Resources Corp. (TSXV: AL) (FSE: 6LLN) (OTC: ALXEF) ("ALX" or the "Company") is pleased to announce the results of matters voted on at the Company's Annual General and Special Meeting of shareholders of the Company (the "Shareholders") held this morning at 10:00 AM (Vancouver time) (the "Meeting"). At the Meeting, Shareholders were asked to vote on resolutions approving, among other things, the acquisition by Greenridge Exploration Inc. ("Greenridge") (CSE: GXP) of all of the outstanding and issued common shares of ALX (the "ALX Shares") by way of a court-approved plan of arrangement under the Business Corporations Act (British Columbia) (the "Arrangement"). |
newsfilecorp.com |
2024-12-02 18:05:00 |
Czytaj oryginał (ang.) |
| ALX Oncology Appoints Alan Sandler, M.D., as Chief Medical Officer |
Dr. Sandler brings more than 30 years of experience as a distinguished leader in oncology and drug development Dr. Sandler brings more than 30 years of experience as a distinguished leader in oncology and drug development |
globenewswire.com |
2024-11-14 10:00:00 |
Czytaj oryginał (ang.) |
| Alexander's Is A Good Business That The Market Has Overestimated |
Alexander's, Inc. has underperformed since 2019, with a -1.7% TSR compared to SPY's 113%, due to declining profitability and rich valuations. Despite increasing NOPAT since 2020, the Company's GAAP net income and NOPAT margins have declined from 2019 highs, impacting overall profitability. Management has created value with $154 million in economic earnings since 2019, but ALX remains overvalued with unrealistic growth expectations. |
seekingalpha.com |
2024-11-12 08:00:24 |
Czytaj oryginał (ang.) |
| A Decisive Realignment |
U.S. equity markets soared to record highs this week after President-elect Trump scored a surprisingly decisive election victory, including a likely "trifecta" of Republican legislative control in Congress. The outcome sparked powerful moves across global financial markets as investors priced in a combination of domestic-focused and "pro-growth" economic policies but also reflected concern over deficits and immigration policy. Characteristic of the "Trump trade" dynamic, smaller-cap companies led the surge, outperforming mega-cap technology and international-heavy peers. The S&P Small-Cap 600 soared 9%, outpacing 5% gains from the S&P 500. |
seekingalpha.com |
2024-11-10 11:00:00 |
Czytaj oryginał (ang.) |
| ALX Oncology Reports Third Quarter 2024 Financial Results and Provides Corporate Update |
SOUTH SAN FRANCISCO, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer in new ways and extend patients' lives, today reported financial results for the third quarter ended September 30, 2024, and provided a corporate update. |
globenewswire.com |
2024-11-07 18:00:00 |
Czytaj oryginał (ang.) |
| ALX Resources Corp. Announces Filing and Mailing of the Management Information Circular in Connection with Its Annual and Special Meeting of Shareholders to Approve the Acquisition of the Company by Greenridge Exploration Inc. |
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES Vancouver, British Columbia--(Newsfile Corp. - November 7, 2024) - ALX Resources Corp. (TSXV: AL) (FSE: 6LLN) (OTC: ALXEF) ("ALX" or the "Company") is pleased to announce that its management information circular (the "ALX Circular") and related materials (collectively, the "Materials") in connection with the Annual General and Special Meeting (the "Meeting") of its shareholders (the "ALX Shareholders") is now available on ALX's website ( click here to access the Materials) as well as under ALX's profile on SEDAR+ (www.sedarplus.ca). The Company commenced the mailing of the Materials for the Meeting to ALX Shareholders on Tuesday, November 5, 2024. |
newsfilecorp.com |
2024-11-07 09:30:00 |
Czytaj oryginał (ang.) |
| Alexander's (ALX) Tops Q3 FFO and Revenue Estimates |
Alexander's (ALX) came out with quarterly funds from operations (FFO) of $2.84 per share, beating the Zacks Consensus Estimate of $2.57 per share. This compares to FFO of $3.63 per share a year ago. |
zacks.com |
2024-11-04 12:55:32 |
Czytaj oryginał (ang.) |
| Alexander's Announces Third Quarter Financial Results |
PARAMUS, N.J., Nov. 04, 2024 (GLOBE NEWSWIRE) -- ALEXANDER'S, INC. (New York Stock Exchange: ALX) filed its Form 10-Q for the quarter ended September 30, 2024 today and reported: |
globenewswire.com |
2024-11-04 11:16:00 |
Czytaj oryginał (ang.) |
| ALX Oncology Announces Results from Phase 1b/2 Trial of Evorpacept in Combination with Zanidatamab will be Presented at the San Antonio Breast Cancer Symposium (SABCS) 2024 |
Poster presentation will highlight new data from clinical trial evaluating evorpacept, a highly differentiated investigational CD47 blocker, in combination with zanidatamab, an investigational dual HER2-targeted bispecific antibody, in patients with advanced breast cancers Poster presentation will highlight new data from clinical trial evaluating evorpacept, a highly differentiated investigational CD47 blocker, in combination with zanidatamab, an investigational dual HER2-targeted bispecific antibody, in patients with advanced breast cancers |
globenewswire.com |
2024-11-01 19:30:00 |
Czytaj oryginał (ang.) |
| Alexander's Declares Quarterly $4.50 Dividend on Common Shares |
PARAMUS, N.J., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Alexander's, Inc. (NYSE: ALX) today announced that its Board of Directors has declared a regular quarterly dividend of $4.50 per share payable on November 29, 2024 to stockholders of record on November 11, 2024. |
globenewswire.com |
2024-10-30 15:33:00 |
Czytaj oryginał (ang.) |
| Alexander's Announces Third Quarter Earnings Release Date and Vornado Realty Trust Quarterly Conference Call |
PARAMUS, N.J., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Alexander's, Inc. (NYSE: ALX) today announced that it will file its quarterly report on Form 10-Q for the quarter ended September 30, 2024 with the U.S. Securities and Exchange Commission and issue its third quarter earnings release on Monday, November 4, 2024, before the New York Stock Exchange opens. |
globenewswire.com |
2024-10-22 17:45:00 |
Czytaj oryginał (ang.) |
| Greenridge Exploration Enters into Binding Arrangement Agreement to Acquire ALX Resources Corp. |
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES Vancouver, British Columbia--(Newsfile Corp. - October 11, 2024) - Greenridge Exploration Inc. (CSE: GXP) (FSE: HW3) ("Greenridge" or the "Company") and ALX Resources Corp. ("ALX" and collectively with Greenridge, the "Parties") (TSXV: AL) (FSE: 6LLN) (OTC: ALXEF) are pleased to announce the signing of a binding arrangement agreement (the "Arrangement Agreement") dated October 11, 2024 pursuant to which Greenridge will acquire all of the outstanding and issued common shares of ALX (the "Transaction"). The Transaction is an arm's length transaction that will create a leading Canadian uranium exploration company with interests in sixteen (16) uranium exploration projects that total approximately 220,000 hectares across renowned Canadian uranium districts including the Athabasca Basin, Thelon Basin and Elliot Lake. |
newsfilecorp.com |
2024-10-11 18:12:00 |
Czytaj oryginał (ang.) |
| An October Surprise |
U.S. equity markets extended gains to a fourth-straight week despite a resurgence in benchmark interest rates after a critical slate of employment data showed surprisingly strong labor market trends. One of several strong employment reports, Nonfarm Payrolls data showed that the U.S. economy added 254k jobs in September - the strongest in six months and well above consensus estimates. Combined with a nearly 10% surge in crude oil prices driven by renewed Middle East tensions, markets reflected a significantly less aggressive Fed rate cut path in the months ahead. |
seekingalpha.com |
2024-10-06 13:00:00 |
Czytaj oryginał (ang.) |
| Alexander's Completes $400 Million Refinancing of 731 Lexington Avenue Office Condominium |
PARAMUS, N.J., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Alexander's, Inc. (NYSE: ALX) today announced that it has completed a $400 million refinancing of the office condominium portion of 731 Lexington Avenue, the Class A Bloomberg LP headquarters building. The interest-only loan carries a fixed rate of 5.045% and matures in October 2028. The loan is prepayable, at Alexander's option, with no penalty, beginning in October 2026. |
globenewswire.com |
2024-09-30 20:27:00 |
Czytaj oryginał (ang.) |
| Fed Rate Cuts Breathe New Life Into These High-Yield Stocks |
Real estate is great, except for the heavy time commitment, which makes it a non-starter for me. “Brett, can you come over and change my lightbulb? |
forbes.com |
2024-09-29 15:01:00 |
Czytaj oryginał (ang.) |
| Best Income Stocks to Buy for September 18th |
ALX, JSAIY and NBTB made it to the Zacks Rank #1 (Strong Buy) income stocks list on September 18, 2024. |
zacks.com |
2024-09-18 13:50:34 |
Czytaj oryginał (ang.) |
| New Strong Buy Stocks for September 18th |
SN, ALX, BPOP, ARCAY and JSAIY have been added to the Zacks Rank #1 (Strong Buy) List on September 18, 2024. |
zacks.com |
2024-09-18 11:36:04 |
Czytaj oryginał (ang.) |
| Best Income Stocks to Buy for September 13th |
BANF, ALX and BPRN made it to the Zacks Rank #1 (Strong Buy) income stocks list on September 13, 2024. |
zacks.com |
2024-09-13 09:50:50 |
Czytaj oryginał (ang.) |
| ALX Oncology's Evorpacept Gains Momentum With FDA Fast Track Designations |
ALX Oncology's Evorpacept, a first-in-class CD47 inhibitor, shows promising results in cancer treatment with reduced side effects and a favorable safety profile. Evorpacept's combination with TRP demonstrated improved response rates and longer duration of response in HER2-positive gastric and GEJ cancer trials. The ASPEN-06 trial also showed favorable results, with a 40.3% ORR in HER2-positive gastric/GEJ cancer, higher than the control group's 26.6%. |
seekingalpha.com |
2024-09-12 02:36:27 |
Czytaj oryginał (ang.) |